June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Bile acid receptor signaling in oxygen oxygen-induced retinopathy
Author Affiliations & Notes
  • Menaka Thounaojam
    Ophthalmology, Augusta University, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Allston Oxenrider
    Ophthalmology, Augusta University, Augusta, Georgia, United States
  • Vijay C Ganta
    Medicine, Augusta University, Augusta, Georgia, United States
    Vascular Biology Center, Augusta University, Augusta, Georgia, United States
  • Pamela M Martin
    Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Ravirajsinh Jadeja
    Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Menaka Thounaojam None; Allston Oxenrider None; Vijay Ganta None; Pamela Martin None; Ravirajsinh Jadeja None
  • Footnotes
    Support  EY034568
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 587. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Menaka Thounaojam, Allston Oxenrider, Vijay C Ganta, Pamela M Martin, Ravirajsinh Jadeja; Bile acid receptor signaling in oxygen oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2023;64(8):587.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinopathy of prematurity (ROP) is the leading cause of blindness in premature infants, and available therapies are often associated with severe side effects. Our previous studies using RNA-sequencing have demonstrated disruption of sterol and bile acids (BA) metabolism in an experimental model of ROP (oxygen-induced retinopathy; OIR). Our preliminary data suggested the presence of BA receptors in the retina discloses the existence of BA-related signaling mechanisms and explains their effects in OIR mice. We hypothesized that alterations in retinal farnesoid X receptor (FXR; a nuclear BA receptor) signaling play a key role in ROP pathogenesis and the pharmacological modulation of these pathways represents a new therapeutic tool in limiting ROP pathology.

Methods : Changes in mRNA expression of various BA receptors in the developing mice retina were studied using qPCR. mRNA and protein expression of FXR receptor in postnatal and OIR mice retinas were studied using qPCR and western blotting assays. In addition, seven days old (P7) wild-type (WT) and FXR-/- mice were subjected to the OIR procedure, retinas were collected at P17, and retinal flat mounts were stained with isolectin B4 to study vascular distribution in these mice retinas. Lastly, WT mice were treated with an FXR agonist, obeticholic acid (OCA; 50 mg/kg/day from P7-P17), and the vascular pathology in OIR mice were analyzed at P17.

Results : FXR was the most highly expressed nuclear BA receptor. While the FXR expression remained consistent throughout the retinal development and adult retina, its expression significantly decreased in OIR mice compared to RA. Further results obtained using FXR-/- mice indicated that the absence of FXR does not affect normal vasculature development; it plays a significant role in OIR pathology. Lastly, treatment with OCA improved the vascular pathology in OIR mice, as evidenced by the decreased number of neovascular tufts and size of the avascular areas compared to untreated OIR mice. Further unbiased vascular network analysis revealed that OCA-treated mice had increased vessel length, junction density, and fewer endpoints compared to untreated OIR mice retina vasculature.

Conclusions : Our data suggest that endogenous retinal BA synthesis and subsequent FXR signaling are compromised in OIR mice, OIR pathology is exacerbated in FXR null mice and is ameliorated by an FXR-specific agonist, OCA.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×